A new group of 40-something professionals in central Indiana is hoping to do for education reform what the amateur sports initiative did 35 years ago: spawn a generation of leaders to work on a long-term challenge.
Insiders at Indianapolis-area companies cashed in millions of dollars of their own companies’ shares this month, a selling spree that might reflect growing sentiment the market rally is ending.
Researchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.
Do the politicians care what nonvoters think? House Speaker Brian Bosma recently took issue with the WISH-TV/Ball State Hoosier Survey because, he said, it wasn’t a voter poll. When challenged, he said that he cares what everybody thinks, but the message he delivered was that the opinions of voters matter more than those of adults who don’t get to the polls.
Do the politicians care what nonvoters think? House Speaker Brian Bosma recently took issue with the WISH-TV/Ball State Hoosier Survey because, he said, it wasn’t a voter poll. When challenged, he said that he cares what everybody thinks, but the message he delivered was that the opinions of voters matter more than those of adults […]
Purdue University has hired a former official in Mitch Daniels' gubernatorial administration to lead the Purdue Research Foundation.
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases.
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases, Bloomberg News reported. Lilly wants a court to reaffirm the patents behind its own cancer drug Erbitux. According to Lilly’s lawsuit, filed Thursday in federal court in San Francisco, Genentech deceived the U.S. Patent Office into issuing patents known as “Cabilly” after one of the inventors. Genentech claims that the process and certain starting materials used to produce Erbitux infringe on parts of the patents, and is pursuing an “aggressive litigation policy to protect its products against competition,” according to the complaint. Erbitux, made by Indianapolis-based Lilly’s ImClone unit, is approved in the United States to treat colon cancer and head and neck tumors. Lilly realized about $400 million in revenue from the drug in 2012. A phone call to Genentech’s media office seeking comment about the lawsuit wasn’t immediately returned.
Indianapolis-based CHV Capital joined Kaiser Permanente Ventures to invest an $8 million funding round for Health Catalyst, a Salt Lake City-based data warehousing company. The company already had raised $33 million in Series B funding to develop its technology, which helps hospitals measure quality data from their electronic medical record systems and report it to regulatory agencies and health insurers. Indiana University Health, the hospital system that is the parent of CHV Capital, already is using Health Catalyst’s technology.
The Indiana Senate voted last week to expand Medicaid using the state-run Healthy Indiana Plan. According to the Associated Press, Gov. Mike Pence and the Republican-led General Assembly have beat back efforts by Democrats to expand coverage using the traditional federal-state Medicaid program for the poor. Instead, they say, expansion should be done through the Healthy Indiana Plan or a similar state-run program, giving the state more control over costs. Expanding HIP would cost the state roughly 3 percent less than expanding Medicaid, state actuary Milliman Inc. estimated on Feb. 25. And supporters say HIP would promote more responsible decisions by enrollees. On the table is an expected $10.5 billion in federal aid for the state over the next seven years. But expanding HIP also could cost the state close to $2 billion over the period. House Speaker Brian Bosma, R-Indianapolis, said Tuesday that Pence likes the Senate's request for block grants from the federal government instead of matching funds for Indiana’s spending, as is the case with traditional Medicaid. "At least the leadership is all in favor of not using Medicaid expansion as the vehicle here because of the potential for massive cost in the future," Bosma said. Seven Democratic senators voted with all of the chamber's Republicans for the expansion, despite reservations about using HIP. "We don't agree with the bill the way it was written, but we want to make sure it remains alive," said Sen. Karen Tallian, D-Portage. Tallian asked lawmakers to approve a temporary expansion of Medicaid, for two years, similar to what Florida Gov. Rick Scott, a Republican, is supporting. But her amendment and similar efforts in the House failed.
Warsaw-based Zimmer Holdings Inc. said the U.S. Securities and Exchange Commission and the U.S. Department of Justice have ended their investigation into a possible violation by Zimmer of the Foreign Corrupt Practices Act. The investigation dates to September 2007. Zimmer is the world’s largest maker of orthopedic implants.
The National Science Foundation has awarded $500,000 to West Lafayette-based Tymora Analytical Operations LLC via a Phase II Small Business Innovation Research grant. Tymora will use the two-year grant to develop a technology called pIMAGO that helps lab researchers identify new targets for drugs to fight such diseases as cancer, diabetes, neurological disorders and immune system disorders. Tymora, founded by two Purdue University professors, has also received $450,000 in previous grants from the National Institutes of Health.
Eli Lilly and Co. and five other big drugmakers avoided paying $7 billion in U.S. taxes last year by shifting their profits overseas. The strategy has drawn the ire of some legislators.
A jury Friday awarded $8.3 million to a former prison guard who accused Warsaw-based DePuy Orthopaedics of knowingly marketing a faulty hip implant that was later recalled, according to the Associated Press. Jurors found that the ASR XL implant was defectively designed and caused metal poisoning and other health problems suffered by Loren Kransky after he underwent surgery in 2007. The fraud and negligence suit is the first of nearly 11,000 similar cases involving an all-metal ball-and-socket hip joint that was pulled from the market two years ago to reach trial in the United States. Others like Kransky claim the implants have left them with crippling injuries or in need of other replacement surgeries. DePuy, a subsidiary of New Jersey-based Johnson & Johnson, has set aside about $1 billion to cover costs of the recall and lawsuits.
Eli Lilly and Co. has built up a stockpile of $21 billion in overseas profits as the nation’s largest drugmakers continue to use accounting mechanisms to avoid paying U.S. taxes. According to an analysis by Bloomberg News, the nation's six biggest drugmakers avoided paying $7.05 billion in U.S. taxes last year by shifting their profits overseas—nearly double the savings they achieved a decade ago. Now those legal practices are getting increased scrutiny from members of Congress. “The right kind of tax reform could do a lot to bring corporate profits back to the United States for investment and job creation,” said Charles Grassley, a U.S. senator from Iowa, in an e-mail to Bloomberg. “The current system provides an incentive for companies to keep money overseas indefinitely.” By moving patents and trademarks overseas, drugmakers can legally record sales of their products in foreign countries, avoiding any U.S. taxes until those profits are brought back into the United States. The maneuvers helped Lilly boost its earnings per share by 16 percent last year, according to Bloomberg. Other companies increased their earnings even more. Lilly declined to comment on the story.
IUPUI students can now pursue an academic minor in neuroscience, in addition to the neuroscience major that began in the fall. The School of Science at IUPUI launched its new neuroscience program to “take advantage of a booming neuroscience industry in Indiana and across the country,” according to a statement issued March 4. The school noted that the Indiana University Health hospital system recently opened a $120 million neuroscience center next to Methodist Hospital. And the IU School of Medicine is building a neuroscience research center next door to the IU Health facility. Neuroscience is one of several fast-growing segments of the life sciences industry in Indiana. A forecast by the Indiana Department of Workforce Development predicts that life scientist positions will increase by more than 22 percent in the next five years.
More than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
Indiana manufacturers and consumer groups opposed to a bill that would make it easier for power companies to raise their rates won concessions Wednesday from House lawmakers.
A fixture in Indianapolis' startup community, Marcadia Biotech co-founder Kent Hawryluk is backing a project management software firm.
Shares of several pharmaceutical companies that make diabetes medicines, including Eli Lilly, fell after U.S. regulators warned they are looking into potential risks of drugs in two classes of diabetes treatments.
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
The Mind Trust education reform group has agreed to give $1 million each to two California-based charter school networks that plan to open 12 new schools here in the next seven years.
Eli Lilly and Co. shares have more than doubled over the past four years, an impressive run-up that has as much to do with the company’s well-crafted investor-relations message as it does scientific innovation.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
Eli Lilly and Co. granted larger bonuses to its top five executives early this year, which boosted their 2012 compensation anywhere from 3 percent to 8 percent.
